Core Insights - The A-share market experienced fluctuations with the Shanghai Composite Index falling by 0.96% to 4117.95 points, while the Shenzhen Component Index decreased by 0.66%. The ChiNext Index, however, rose by 1.27% [1][7] - The total trading volume in the A-share market was 2.86 trillion RMB, with nearly 2900 stocks declining. The communication sector led the gains, while the non-ferrous metals sector saw the largest losses [1][7] - In the Hong Kong market, the Hang Seng Index dropped by 2.08%, and the Hang Seng Tech Index fell by 2.1%. In the overseas markets, all three major U.S. stock indices declined, with the Dow Jones down by 0.36%, the S&P 500 down by 0.43%, and the Nasdaq down by 0.94% [1][7] Important News - The Central Committee of the Communist Party of China emphasized the acceleration of the new round of technological revolution and industrial transformation, highlighting the importance of leveraging comparative advantages to promote breakthroughs in future industries [2][8] - The National Bureau of Statistics reported that the manufacturing PMI for January was 49.3%, a decrease of 0.8 percentage points month-on-month. The non-manufacturing PMI also fell to 49.4%, indicating a decline in business activity due to seasonal factors and insufficient market demand [2][8] Sector Analysis - In the social services sector, the proportion of heavy positions in funds increased, with 286 funds holding shares, up by 109 from the previous quarter. The total market value of holdings reached 5.57 billion RMB, an increase of 0.975 billion RMB [9][10] - The heavy position ratio for the social services sector was 0.06%, up by 0.01 percentage points, ranking 27th among 31 sectors, indicating potential for rebound as it remains below the 5-year average of 0.34% [9][10] - The hospitality and restaurant sectors showed slight recovery, while the education sector saw a significant decline in heavy position ratios [9][10] Individual Stocks - Leading stocks in the social services sector saw increased holdings, with the top ten stocks' combined heavy position ratio rising to 0.058%, an increase of 0.013 percentage points from the previous quarter. Notable stocks include Huace Testing, Shoulv Hotel, and JiuHua Tourism [10][11] - The report suggests focusing on companies benefiting from the upcoming long holiday and those positioned to take advantage of the Hainan Free Trade Port's opportunities [11] Beauty and Personal Care Sector - The beauty and personal care sector saw a decrease in fund allocation, with the total market value of A-shares at 255.096 billion RMB, down by 10.43% from the previous quarter. The fund allocation ratio was 0.14%, a decrease of 0.06 percentage points [12][13] - The personal care and cosmetics segments remain in a low allocation zone, while the medical beauty segment is in an over-allocated position [12][13] - Key stocks in the beauty and personal care sector include Jinbo Biological, Aimeike, and Baiya Shares, with their heavy position ratios declining compared to the previous quarter [14]

Investment Rating - The investment rating for the beauty and personal care industry is "outperforming the market" [4][22]. Core Insights - The fund allocation ratio for the beauty and personal care industry decreased to 0.14% in Q4 2025, down 0.06 percentage points from Q3 2025, indicating a continued low allocation status [1][3][9]. - The total market capitalization of the beauty and personal care industry reached 255.096 billion yuan in Q4 2025, reflecting a 10.43% decrease from Q3 2025 [1][9]. - The medical beauty sector remains in an over-allocated position, while personal care and cosmetics are in a low allocation zone [2][11]. Summary by Sections Industry Overview - In Q4 2025, the fund allocation ratio for personal care products was 0.03%, down 0.01 percentage points from Q3 2025, with an over-allocation ratio of -0.04% [2][13]. - The cosmetics sector saw a fund allocation ratio of 0.02% in Q4 2025, down 0.02 percentage points from Q3 2025, with an over-allocation ratio of -0.1% [2][13]. - The medical beauty sector's fund allocation ratio was 0.09% in Q4 2025, down 0.03 percentage points from Q3 2025, with an over-allocation ratio of 0.02% [2][13]. Individual Stocks - The top three stocks in the beauty and personal care sector by fund allocation in Q4 2025 were Jinbo Biological, Aimeike, and Baiya Shares, with a total heavy holding ratio of 0.05%, down 0.02 percentage points from Q3 2025 [2][15][19]. - Jinbo Biological had a heavy holding ratio of 0.0163%, Aimeike at 0.0156%, and Baiya Shares at 0.0040% in Q4 2025, all showing a decline compared to Q3 2025 [15][19]. Investment Recommendations - In the context of stabilizing the economy and expanding domestic demand, it is recommended to focus on: 1. Cosmetics and medical beauty: There is significant demand potential in the medium to long term, supported by regulatory policies favoring compliant companies [3][20]. 2. Personal care products: The growing emphasis on health and wellness among consumers suggests opportunities for leading companies with strong R&D capabilities [3][20].

证券之星消息，1月30日医疗美容板块较上一交易日下跌3.14%，爱美客领跌。当日上证指数报收于 4117.95，下跌0.96%。深证成指报收于14205.89，下跌0.66%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.07 | -1.92% | 12.54万 | 3883.90万 | | 920982 | 锦波生物 | 221.39 | -2.42% | 7085.98 | 1.58亿 | | 688363 | 华熙生物 | 44.83 | -3.20% | 4.64万 | 2.10亿 | | 300896 | 爱美客 | 139.73 | -3.22% | 3.76万 | 5.31亿 | 从资金流向上来看，当日医疗美容板块主力资金净流出7658.45万元，游资资金净流入4438.38万元，散户 资金净流入3220.06万元。医疗美容板块个股资金流向见下表： | 代码 | | | | 名称 ｜主力净流入（元）｜主力净占比｜ ...

Core Viewpoint - *ST Meigu's 2025 performance forecast indicates expected revenue of approximately 850 to 1,050 million yuan, with a net loss attributable to shareholders projected between 550 to 390 million yuan. The company anticipates a significant increase in net assets by the end of the period due to the completion of its restructuring plan [1][1]. Group 1 - The company received a civil ruling from the Intermediate People's Court of Xiangyang on December 29, 2025, confirming the completion of its restructuring plan, which has effectively resolved its debt crisis and significantly improved its asset-liability structure [1][1]. - The restructuring involved introducing investors and adjusting equity, leading to a substantial increase in the company's net assets by the end of the reporting period [1][1]. Group 2 - The medical beauty business faces increasing competition and challenges in customer acquisition, resulting in a year-on-year decrease in revenue and profit, prompting the company to make impairment provisions for related assets [1][1]. - The biobased fiber business has not shown effective improvement, leading the company to also make impairment provisions for relevant production lines [1][1].

Company Overview - The company primarily operates in the bio-based fiber and medical beauty sectors [6] - It expects to achieve operating revenue of approximately 850 to 1,050 million yuan in 2025, with a net loss attributable to shareholders ranging from 550 to 390 million yuan [6] Financial Performance - The company has undergone a restructuring process, which has significantly improved its debt situation and asset-liability structure, leading to a substantial increase in net assets by the end of the reporting period [6] - The medical beauty business has faced intensified competition, resulting in a decrease in both revenue and profit, prompting the company to make impairment provisions for related assets [6] - The bio-based fiber business has not shown effective improvement, leading to additional impairment provisions for relevant production lines [6] Revenue and Profit Trends - Historical total revenue and net profit figures indicate fluctuations, with total revenue projected to decline in 2022 and 2023, followed by a recovery in 2024 and 2025 [7] - The year-on-year growth rates for total revenue and net profit have shown significant variability, with a notable decline of 36.92% in 2022 and a projected recovery of 19.77% in 2024 [7]

南财智讯1月29日电，*ST美谷发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为亏 损3.90亿元—5.50亿元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为亏损5.50 亿元—7.80亿元。公司预计2025年实现营业收入约8.5至10.5亿元，归属于上市公司股东的净利润亏损约 5.5至3.9亿元，预计期末净资产转正并大幅增长，主要原因如下：1、2025年12月29日，公司收到湖北省 襄阳市中级人民法院（以下简称"襄阳中院"）送达的（2025）鄂06破17号之一《民事裁定书》，鉴于相 关事项已达到《奥园美谷科技股份有限公司重整计划》（以下简称《重整计划》）第七部分第四条规定 的执行完毕标准，《重整计划》已经执行完毕，襄阳中院裁定终结公司重整程序。在重整程序中，公司 通过引入重整投资人、实施出资人权益调整等方式，有效化解了公司债务危机，极大地改善了公司资产 负债结构，大幅提高了公司期末净资产。2、报告期内，医疗美容业务市场竞争越趋激烈、客户开拓难 度加大，公司医疗美容业务营业收入和利润同比有所减少，公司对相关资产计提了减值准备；生物基纤 维业务经营未得到有效改善，公司对相关生 ...

Core Insights - The medical beauty sector experienced a rise of 2.96% on January 29, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Medical Beauty Sector Performance - Ai Meike (300896) closed at 144.38, with a gain of 4.53%, trading volume of 56,700 shares, and a transaction value of 803 million [1] - Huaxi Biological (688363) closed at 46.31, up 1.47%, with a trading volume of 45,900 shares and a transaction value of 211 million [1] - Jinbo Biological (920982) closed at 226.88, up 1.35%, with a trading volume of 8,287 shares and a transaction value of 1.86 billion [1] - ST Meigu (000615) closed at 3.13, down 1.26%, with a trading volume of 103,100 shares and a transaction value of 32.32 million [1] Capital Flow Analysis - The medical beauty sector saw a net inflow of 105 million from main funds, while retail investors experienced a net outflow of 33.44 million [1] - Ai Meike had a main fund net inflow of 103 million, representing 12.77%, with retail outflows of 38.71 million [2] - Huaxi Biological had a main fund net inflow of 10.25 million, representing 4.86%, with retail outflows of 1.15 million [2] - Jinbo Biological had a main fund net inflow of 9.45 million, representing 5.09%, with retail inflows of 1.25 million [2] - ST Meigu had a main fund net outflow of 7.90 million, representing -24.43%, with retail inflows of 4.02 million [2]

Core Viewpoint - The company forecasts a significant increase in adjusted net profit for 2025, driven by a dual strategy of organic growth and external acquisitions, leading to improved profitability and operational efficiency [1][2]. Group 1: Financial Performance Forecast - The company expects 2025 revenue to be no less than 3 billion yuan, representing a year-on-year growth of at least 16% [1]. - Adjusted net profit is projected to be no less than 380 million yuan, with a year-on-year increase of at least 40%, while net profit is expected to be no less than 340 million yuan, reflecting a growth of at least 34% [1]. - The performance forecast aligns with expectations due to the company's effective dual strategy and operational improvements [1]. Group 2: Growth Drivers - The company anticipates robust organic growth and contributions from acquisitions, with revenue growth expected to be driven by double-digit growth in beauty and health services, and high growth in sub-health medical services [1][2]. - The integration of the acquired company, Nai Rui Er, is expected to enhance operational efficiency and contribute to revenue growth in 2025 [1][2]. - The company reported strong performance during the year-end "Double Festival" period, with revenue from its main business segments showing positive year-on-year growth [1]. Group 3: Profitability Enhancement - The company forecasts an adjusted net profit margin of 12.7% for 2025, an increase of 2 percentage points year-on-year, driven by a higher proportion of high-margin medical services and operational efficiency improvements [2]. - The integration of Nai Rui Er is expected to further enhance profitability through effective resource integration and operational empowerment [2]. Group 4: Strategic Outlook - The company completed the acquisition of Si Yan Li on January 7, 2026, which will contribute to revenue growth and operational efficiency, leveraging the integration experience from Nai Rui Er [2]. - The company is optimistic about its growth potential under the "super brand, super chain, super digitalization" strategy, which is expected to enhance market bargaining power [2]. Group 5: Earnings Forecast and Valuation - The company maintains its profit forecast for 2025 and has increased the 2026 net profit estimate by 20% to 430 million yuan, with projections for 2027 at 540 million yuan [2]. - The current stock price corresponds to a price-to-earnings ratio of 13x for 2026 and 10x for 2027, with a target price of 42 HKD, indicating a potential upside of 57% [2].

Core Viewpoint - Shanghai Zhuoruixiang Medical Beauty Clinic Co., Ltd. has been established with a registered capital of 2 million RMB, fully owned by Shenzhen Zhuozheng Medical Consulting Co., Ltd. [1] Company Information - The legal representative of the company is Shi Xiaojian [1] - The registered capital is 2 million RMB [1] - The company is classified as a limited liability company with natural person investment or control [1] - The business address is located in the China (Shanghai) Pilot Free Trade Zone, Jinhu Road [1] Shareholding Structure - Shenzhen Zhuozheng Medical Consulting Co., Ltd. holds 100% of the shares [1] Business Scope - The business scope includes medical beauty services, medical services, clinic services, sales of Class II medical devices, and health consulting services (excluding diagnosis and treatment services) [1] - The company can also engage in retail of cosmetics, personal hygiene products, and glasses (excluding contact lenses), as well as provide technical services, development, consulting, and transfer [1] - The company is authorized to conduct business activities independently based on its business license, except for projects that require approval from relevant authorities [1]

Market Overview - The medical beauty sector experienced a decline of 1.57% on January 28, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] Stock Performance - Key stocks in the medical beauty sector showed the following performance: - *ST Meigu closed at 3.17, down 0.63% with a trading volume of 66,700 shares and a turnover of 21.20 million yuan [1] - Aimeike closed at 138.12, down 1.56% with a trading volume of 29,800 shares and a turnover of 413 million yuan [1] - Huaxi Biological closed at 45.64, down 1.70% with a trading volume of 28,800 shares and a turnover of 13.20 million yuan [1] - Jinbo Biological closed at 223.85, down 1.97% with a trading volume of 7,323 shares and a turnover of 165 million yuan [1] Capital Flow - The medical beauty sector saw a net outflow of 49.81 million yuan from main funds, while retail investors had a net inflow of 55.20 million yuan [1] - Detailed capital flow for key stocks includes: - *ST Meigu: Main funds net outflow of 1.98 million yuan, retail net inflow of 1.61 million yuan [2] - Huaxi Biological: Main funds net outflow of 9.06 million yuan, retail net inflow of 3.16 million yuan [2] - Jinbo Biological: Main funds net outflow of 25.03 million yuan, retail net inflow of 0.38 million yuan [2] - Aimeike: Main funds net outflow of 38.77 million yuan, retail net inflow of 50.43 million yuan [2]